Get notified when VRDN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsViridian announces topline results from REVEAL-2 phase 3 trial of elegrobart
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
high
Viridian disclosed topline data from its REVEAL-2 phase 3 clinical trial testing elegrobart, a subcutaneous antibody treatment, in patients with chronic thyroid eye disease. The actual trial outcomes are not detailed in the 8-K filing itself.
Item 8.01 view on EDGAR → -
medium
The company updated its corporate presentation to include the REVEAL-2 topline results, providing investors with current clinical trial data and company positioning.
Exhibit 99.2 view on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade VRDN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify